Please assess the completion status of the following clinical trial:

Trial Title: Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* Participants with T1DM or T2DM (T2DM US only) diagnosed for at least 12 months, who have been treated with a multiple daily injection regimen with~* NovoLog/NovoRapid or insulin lispro (100 U/mL) in the last 6 months prior to screening visit AND~* insulin glargine (100 U/mL) in the last 6 months prior to screening visit OR insulin detemir (Levemir®) in the last 12 months prior to screening visit.~Exclusion criteria:~* At screening visit, age under legal age of adulthood.~* HbA1c \<7.0% or greater than (\>) 10% at screening.~* Less than 1 year on continuous insulin treatment.~* Use of insulin pump in the last 3 months before screening visit.~* Participants with incomplete baseline 7-point SMPG profile, defined as participants who do not have 7-point profiles with at least 5 points on at least 2 days in the week before randomization Visit 3.~* Participants with T1DM: Use of glucose lowering agents other than insulin including use of non-insulin injectable peptides in the last 3 months prior to screening.~* Participants with T2DM:~  * Use of glucagon-like peptide-1 (GLP-1) receptor agonists in the last 3 months before screening visit.~ * Use of oral antidiabetic drugs (OADs) not on stable dose in the last 3 months before screening visit (sulfonylureas was discontinued at baseline).~* At screening visit, body mass index (BMI) greater than or equal to (\>=) 35 kilogram per meter square (kg/m\^2) in participants with T1DM and \>=40 kg/m\^2 in participants with T2DM.~* Use of insulin other than:~  * insulin glargine 100 U/mL and NovoLog/NovoRapid or insulin lispro 100 U/mL as part of a multiple injection regimen in the last 6 months before screening visit, OR~ * insulin detemir 100 U/mL in the 12 months before screening visit and NovoLog/NovoRapid or insulin lispro 100 U/mL in the last 6 months before screening visit as part of a multiple injection regimen.~* Status post pancreatectomy.~* Status post pancreas and/or islet cell transplantation.~* Hospitalization for recurrent diabetic ketoacidosis in the last 3 months before screening visit.~* History of severe hypoglycemia requiring Emergency Room admission or hospitalization in the last 3 months before screening visit.~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.~* Pregnant or breastfeeding women.~* Women of childbearing potential not protected by highly effective method(s) of birth control.~The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR341402 (Type: EXPERIMENTAL): SAR341402 subcutaneous (SC), before meals intake on top of once daily (QD) Insulin Glargine, up to Week 52.
- NovoLog/NovoRapid (Type: ACTIVE_COMPARATOR): NovoLog/NovoRapid SC, before meals intake on top of QD Insulin Glargine, up to Week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).